{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:52Z","timestamp":1792180672533,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115212","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T22:52:54Z","timestamp":1690930374000},"page":"115212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Anticancer clinical efficiency and stochastic mechanisms of belinostat"],"prefix":"10.1016","volume":"165","author":[{"given":"Nasreddine","family":"El Omari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-3515","authenticated-orcid":false,"given":"Saad","family":"Bakrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaad","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Albratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf N.","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8589-7456","authenticated-orcid":false,"given":"Learn-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khang Wen","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Bouyahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115212_bib1","series-title":"Handbook of Epigenetics","first-page":"821","article-title":"Combination epigenetic therapy","author":"Navakauskien\u0117","year":"2023"},{"key":"10.1016\/j.biopha.2023.115212_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2147\/IJGM.S294802","article-title":"Risk of colorectal carcinoma may predispose to the genetic variants of the GST, CYP450, and TP53 genes among nonsmokers in the Saudi community","volume":"14","author":"Sindi","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.biopha.2023.115212_bib3","unstructured":"N.C. Qu\u1ed1c, \\DJ\u1eb7ng Huy Ph\u00fac, B.T.B. Hu\u00ea, N.T. Tu\u00e2n, T.T. M\u1ebfn, Q. De Tran, Synthesis and evaluation of biological activities of two belinostat analogs bearing fluorine at the CAP, VNUHCM Journal of Natural Sciences. 7 (2023) press-press."},{"key":"10.1016\/j.biopha.2023.115212_bib4","doi-asserted-by":"crossref","unstructured":"G. Manzotti, A. Ciarrocchi, V. Sancisi, Inhibition of BET proteins and histone deacetylase (HDACs): Crossing roads in cancer therapy, Cancers. 11 (2019) 304.","DOI":"10.3390\/cancers11030304"},{"key":"10.1016\/j.biopha.2023.115212_bib5","doi-asserted-by":"crossref","unstructured":"S.G. Patel, J.J. Karlitz, T. Yen, C.H. Lieu, C.R. Boland, The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection, The Lancet Gastroenterology & Hepatology. (2022).","DOI":"10.1016\/S2468-1253(21)00426-X"},{"key":"10.1016\/j.biopha.2023.115212_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2023.115212_bib7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115212_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117241","article-title":"The synthesis and evaluation of sulfonamide derivatives target EGFR790M\/L858R mutations and ALK rearrangement as anticancer agents","author":"Cao","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115212_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2019.110981","article-title":"Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors","volume":"206","author":"Kenny","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.biopha.2023.115212_bib10","first-page":"846","article-title":"Histone deacetylase inhibitors as a new anticancer option: how far can we go with expectations? delivery systems","volume":"23","author":"Garmpi","year":"2018","journal-title":"J. BU: Off. J. Balk. Union Oncol."},{"key":"10.1016\/j.biopha.2023.115212_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/15384047.2016.1250046","article-title":"Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma","volume":"17","author":"Havas","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2023.115212_bib12","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/jcmm.12550","article-title":"Belinostat, a potent HDAC i, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling","volume":"19","author":"Valiuliene","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2023.115212_bib13","first-page":"721","article-title":"Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101","volume":"2","author":"Plumb","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.115212_bib14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/CAD.0000000000000122","article-title":"Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells","volume":"25","author":"Savickiene","year":"2014","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.biopha.2023.115212_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.biopha.2023.115212_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115212_bib17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","article-title":"Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours","volume":"46","author":"Mackay","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115212_bib18","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.biopha.2023.115212_bib19","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2011.41.2395","volume":"30","author":"Yeo","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.biopha.2023.115212_bib20","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115212_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2023.115212_bib22","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"JCO"},{"key":"10.1016\/j.biopha.2023.115212_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00280-015-2934-1","article-title":"A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin","volume":"77","author":"Agarwal","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2023.115212_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2090271","article-title":"A phase I\/II clinical trial of Belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas","volume":"2016","author":"Vitfell-Rasmussen","year":"2016","journal-title":"Sarcoma"},{"key":"10.1016\/j.biopha.2023.115212_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00280-019-03955-7","article-title":"Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California cancer consortium NCI\/CTEP sponsored trial","volume":"84","author":"Luu","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115212_bib26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1111\/bcp.14054","article-title":"A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction","volume":"85","author":"Takebe","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115212_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/tomography8020057","article-title":"Final report on clinical outcomes and tumor recurrence patterns of a pilot study assessing efficacy of Belinostat (PXD-101) with chemoradiation for newly diagnosed glioblastoma","volume":"8","author":"Xu","year":"2022","journal-title":"Tomography"},{"key":"10.1016\/j.biopha.2023.115212_bib28","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphomaFDA approval of Belinostat for relapsed or refractory PTCL","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115212_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\u00ae\/CAELYX\u00ae) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115212_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1155\/S1357714X00000062","article-title":"Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC soft tissue and bone sarcoma group","volume":"4","author":"Nielsen","year":"2000","journal-title":"Sarcoma"},{"key":"10.1016\/j.biopha.2023.115212_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bjc.2011.527","article-title":"Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours","volume":"106","author":"Pili","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115212_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2023.115212_bib33","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ijc.23243","article-title":"Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer: investigation of Belinostat in Prostate cancer","volume":"122","author":"Qian","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115212_bib34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and Belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115212_bib35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2407-12-226","article-title":"Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer","volume":"12","author":"Dovzhanskiy","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2023.115212_bib36","first-page":"711","article-title":"Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models","volume":"40","author":"Gravina","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2023.115212_bib37","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.juro.2014.11.091","article-title":"Combination treatment of renal cell carcinoma with Belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase","volume":"193","author":"Kim","year":"2015","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2023.115212_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-1059","article-title":"Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model","volume":"77","author":"Llopiz","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.115212_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","article-title":"Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model","volume":"68","author":"Llopiz","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2023.115212_bib40","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.201000033","article-title":"Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat","volume":"31","author":"Beck","year":"2010","journal-title":"Electrophoresis"},{"key":"10.1016\/j.biopha.2023.115212_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2016.07.023","article-title":"A novel combinatorial strategy using Seliciclib\u00ae and Belinostat\u00ae for eradication of non-small cell lung cancer via apoptosis induction and BID activation","volume":"381","author":"Ong","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.115212_bib42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s10637-016-0372-5","article-title":"Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor \u2013 belinostat \u2013 in glioblastoma cell lines: a preliminary report","volume":"34","author":"Kusaczuk","year":"2016","journal-title":"Investig. N. Drugs"},{"key":"10.1016\/j.biopha.2023.115212_bib43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1878-0261.12064","article-title":"Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma","volume":"11","author":"Kong","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2023.115212_bib44","doi-asserted-by":"crossref","first-page":"41572","DOI":"10.18632\/oncotarget.15017","article-title":"Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.115212_bib45","doi-asserted-by":"crossref","DOI":"10.3892\/or.2020.7563","article-title":"17\u2013AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA\u2011MB\u2011231 breast cancer cells","author":"Zuo","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2023.115212_bib46","doi-asserted-by":"crossref","first-page":"941","DOI":"10.5455\/annalsmedres.2020.07.747","article-title":"Apoptotic effect of Belinostat (PXD101) on MCF-7 cancer cells","volume":"28","author":"Tuncer","year":"2021","journal-title":"Ann. Med. Res."},{"key":"10.1016\/j.biopha.2023.115212_bib47","unstructured":"J. Ferlay, M. Ervik, F. Lam, M. Colombet, L. Mery, M. Pi\u00f1eros, A. Znaor, I. Soerjomataram, F. Bray, Global cancer Observatory: cancer today. Lyon, France: international agency for research on cancer, (2018)."},{"key":"10.1016\/j.biopha.2023.115212_bib48","doi-asserted-by":"crossref","unstructured":"J.R. Molina, P. Yang, S.D. Cassivi, S.E. Schild, A.A. Adjei, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, in: Mayo Clinic Proceedings, Elsevier, 2008: pp. 584\u2013594.","DOI":"10.1016\/S0025-6196(11)60735-0"},{"key":"10.1016\/j.biopha.2023.115212_bib49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2023.115212_bib50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3892\/ol.2011.533","article-title":"Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene","volume":"3","author":"Hirose","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2023.115212_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","article-title":"Pharmacogenetics of irinotecan metabolism and transport: an update","volume":"20","author":"Smith","year":"2006","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.biopha.2023.115212_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/ijms17010138","article-title":"The TEAD family and its oncogenic role in promoting tumorigenesis","volume":"17","author":"Zhou","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115212_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/9783527800315.ch3","article-title":"The discovery and development of belinostat","volume":"2","author":"Finn","year":"2016","journal-title":"Success. Drug Discov."},{"key":"10.1016\/j.biopha.2023.115212_bib54","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115212_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110417","article-title":"Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: from theory to therapy","volume":"120","author":"Guo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2023.115212_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp. Hematol. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222301003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222301003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:31:44Z","timestamp":1777879904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222301003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":56,"alternative-id":["S075333222301003X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115212","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer clinical efficiency and stochastic mechanisms of belinostat","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115212"}}